Ratings Wuhan Huakang Century Medical Co., Ltd.

Equities

301235

CNE1000057D4

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
19.68 ^CNY	+0.92%		-2.86%	-23.21%

Apr. 26	Wuhan Huakang Century Medical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 26	Wuhan Huakang Century Medical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Its low valuation, with P/E ratio at 9.07 and 5.82 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
The company appears to be poorly valued given its net asset value.
Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Construction & Engineering

	1st Jan change	Capi.	ESG Refinitiv
WUHAN HUAKANG CENTURY MEDICAL CO., LTD.	-23.21%	288M	-
VINCI	+1.19%	71.36B	C+
LARSEN & TOUBRO LIMITED	-1.78%	56.93B	C+
QUANTA SERVICES, INC.	+22.52%	38.71B	B+
CHINA STATE CONSTRUCTION ENGINEERING CORPORATION LIMITED	+21.83%	33.77B	B
FERROVIAL SE	+12.11%	29.48B	A-
CHINA RAILWAY GROUP LIMITED	+20.42%	21.93B	B-
WSP GLOBAL INC.	+11.86%	19.04B	A
CHINA COMMUNICATIONS CONSTRUCTION COMPANY LIMITED	+39.66%	17.99B	B+
EMCOR GROUP, INC.	+75.63%	17.78B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes